Get the Stockscreener App
2.63
2.23%
-0.06
After Hours:
2.59
-0.04
-1.52%
Gain Therapeutics Inc stock is currently priced at $2.63, with a 24-hour trading volume of 59,244.
It has seen a -2.23% decreased in the last 24 hours and a -17.30% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.70 pivot point. If it approaches the $2.57 support level, significant changes may occur.
Previous Close:
$2.69
Open:
$2.68
24h Volume:
59,244
Market Cap:
$47.48M
Revenue:
$210.70K
Net Income/Loss:
$-22.22M
P/E Ratio:
-1.4451
EPS:
-1.82
Net Cash Flow:
$-17.13M
1W Performance:
+4.78%
1M Performance:
-17.30%
6M Performance:
-2.59%
1Y Performance:
-47.71%
1D Range:
$2.5301
$2.80
52W Range:
$2.00
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
301 500 1556
Address
4800 Montgomery Lane, Suite 220, Bethesda
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Q2 2024 EPS Estimates for Gain Therapeutics, Inc. Cut by Analyst (NASDAQ:GANX) - Defense World
Defense World
Zacks Research Equities Analysts Increase Earnings Estimates for Cincinnati Financial Co. (NASDAQ:CINF) - Defense World
Defense World
Amgen’s Imdelltra Becomes First Bi-specific T-cell engager for Advanced SCLC - BioSpace
BioSpace
Gain Therapeutics (NASDAQ:GANX) Given Buy Rating at HC Wainwright - Defense World
Defense World
Amgen’s Imdelltra Becomes First Bi-specific T-cell engager for Advanced SCLC - BioSpace
BioSpace
BMS’s Breyanzi Secures Fourth FDA Approval, for Follicular Lymphoma - BioSpace
BioSpace
Gain Therapeutics Inc Stock (GANX) Financials Data
Gain Therapeutics Inc (GANX) Revenue 2024
GANX reported a revenue (TTM) of $210.70 thousand for the quarter ending June 30, 2022, a +91.02% rise year-over-year.
Gain Therapeutics Inc (GANX) Net Income 2024
GANX net income (TTM) was -$22.22 million for the quarter ending September 30, 2023, a -37.69% decrease year-over-year.
Gain Therapeutics Inc (GANX) Cash Flow 2024
GANX recorded a free cash flow (TTM) of -$17.13 million for the quarter ending September 30, 2023, a -13.82% decrease year-over-year.
Gain Therapeutics Inc (GANX) Earnings per Share 2024
GANX earnings per share (TTM) was -$1.81 for the quarter ending September 30, 2023, a -34.07% decline year-over-year.
Gain Therapeutics Inc Stock (GANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alder Matthias | Chief Executive Officer |
Dec 21 '23 |
Sale |
2.46 |
206 |
507 |
5,286 |
| Alder Matthias | Chief Executive Officer |
Dec 07 '23 |
Sale |
2.50 |
1,820 |
4,550 |
4,855 |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
0.77%
1.20%
Cap:
|
Volume (24h):